Positive preliminary results have been reported from two pilot clinical trials evaluating the efficacy and safety of the investigational chimeric antigen receptor therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia . The studies, conducted at the University of Pennsylvania's Perelman School of Medicine, demonstrated that 27 of 30 pediatric and adult patients experienced complete remissions after treatment with CTL019.
http://www.formkit.com/news/2014-10-16-000000/leukemia-drug-ctl01-achieves-90-remission-relapsedrefractory-all
http://www.formkit.com/news/2014-10-16-000000/leukemia-drug-ctl01-achieves-90-remission-relapsedrefractory-all
No comments:
Post a Comment